









Markets
/
Stocks
/
nasdaq-howl
/

Werewolf Therapeutics Inc

HOWL

0.863USD

+0.083+10.63%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

23.77MMarket Cap

LossP/E TTM



Werewolf Therapeutics Inc

0.863

+0.083+10.63%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Werewolf Therapeutics Inc

Currency: USD Updated: 2026-03-26

Key Insights

Werewolf Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 90 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.25.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Werewolf Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

90 / 391

Overall Ranking

198 / 4546

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Werewolf Therapeutics Inc Highlights

StrengthsRisks

Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.89M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.89M.

Overvalued

The company’s latest PE is -0.53, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 21.01M shares, decreasing 31.12% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 677.77K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.73.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

6.250

Target Price

+711.69%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of Werewolf Therapeutics Inc is 6.80, ranking 194 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.80

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.66

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.61

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Werewolf Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of Werewolf Therapeutics Inc is 7.66, ranking 91 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.53, which is -36.35% below the recent high of -0.34 and -1316.75% above the recent low of -7.55.

Score

Industry at a Glance

Previous score

7.66

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 90/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

The current earnings forecast score of Werewolf Therapeutics Inc is 8.80, ranking 51 out of 391 in the Biotechnology & Medical Research industry. The average price target is 5.50, with a high of 10.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

6.250

Target Price

+711.69%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Werewolf Therapeutics Inc

HOWL

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of Werewolf Therapeutics Inc is 8.50, ranking 61 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.99 and the support level at 0.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.86

Change

1.64

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(0)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.008

Buy

RSI(14)

62.051

Neutral

STOCH(KDJ)(9,3,3)

50.536

Buy

ATR(14)

0.084

Low Volatility

CCI(14)

67.063

Neutral

Williams %R

13.188

Overbought

TRIX(12,20)

1.040

Buy

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

0.805

Buy

MA10

0.814

Buy

MA20

0.745

Buy

MA50

0.688

Buy

MA100

0.793

Buy

MA200

1.109

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of Werewolf Therapeutics Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 43.28%, representing a quarter-over-quarter decrease of 10.09%. The largest institutional shareholder is The Vanguard, holding a total of 1.41M shares, representing 2.90% of shares outstanding, with 13.85% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

6.68M

MPM Capital Inc.

3.98M

-21.15%

Arkin Bio Ventures LP

2.05M

The Vanguard Group, Inc.

Star Investors

1.41M

+8.46%

MPM BioImpact LLC

2.41M

BofA Global Research (US)

1.83M

-14.03%

Renaissance Technologies LLC

Star Investors

456.00K

+44.17%

Hicklin Daniel J

647.05K

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Werewolf Therapeutics Inc is 1.54, ranking 300 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.60. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.